. Moreover, QT dispersion, a marker of risk for arrhythmia and sudden death, is elevated in kidney transplant recipients after receiving oral treatment (Prograf ) (11). Quantitative relationships between concentration of FK506 and QT prolongation, evaluated in the guinea pig, have shown that delayed ventricular repolarization duration parallels whole blood levels of the drug (22, 23). All these electrical disturbances suggested alterations of ionic currents. Indeed, it was shown that FK506 has a high potential to evoke direct inhibition of outward K + currents (namely I to and I K ) and prolong the action potential (AP) (7, 8, 6 ). In the present study, we show that the effects of FK506 are more complex and include inhibitions of I CaL and I K1 . The effect on I K1 has prominent impact on the AP at low rates of stimulation, resulting in concomitant hyperpolarization of the RMP and prolongation of late repolarizing phase. High pacing rates dramatically enhance the effect on AP duration and, thereby, provide conditions for EADs. Frequency-dependent facilitation of I CaL is involved in this process. ) added extracellularly to block I Na and I CaL , respectively. They were elicited from a HP of -80 mV by test depolarizations (1s) varying between -50 mV and +70 mV at 0.1 Hz. Amplitude of I to was calculated as the difference between peak of fast transient outward current and steady state current at the end of depolarizing pulses. Amplitudes of I K were measured between the holding current and the steady-state current at the end of depolarizations.
release in heart (18) . In addition, FK506 has the ability to delay cardiac repolarization. This effect is manifested as QT prolongation which provides a substrate for ventricular "torsades de pointe" (TdP) tachycardia. Several clinical cases of nearly fatal arrhythmias and TdP have been reported after administration of FK506 at high blood concentration (3, 13, 14, 25) . Moreover, QT dispersion, a marker of risk for arrhythmia and sudden death, is elevated in kidney transplant recipients after receiving oral treatment (Prograf ) (11) . Quantitative relationships between concentration of FK506 and QT prolongation, evaluated in the guinea pig, have shown that delayed ventricular repolarization duration parallels whole blood levels of the drug (22, 23) . All these electrical disturbances suggested alterations of ionic currents. Indeed, it was shown that FK506 has a high potential to evoke direct inhibition of outward K + currents (namely I to and I K ) and prolong the action potential (AP) (7, 8, 6) . In the present study, we show that the effects of FK506 are more complex and include inhibitions of I CaL and I K1 . The effect on I K1 has prominent impact on the AP at low rates of stimulation, resulting in concomitant hyperpolarization of the RMP and prolongation of late repolarizing phase. High pacing rates dramatically enhance the effect on AP duration and, thereby, provide conditions for EADs. Frequency-dependent facilitation of I CaL is involved in this process. In vivo Holter monitoring was performed by telemetry in untethered rats one week latter. FK506
was injected at 3 mg/kg in the muscle of the left thigh, 30 min after the beginning of ECG recordings. The QT interval was normalized into a rate independent corrected value (QTc). We used Bazett's formula : QTc = QT/ RR, where RR is the interval between two R waves. Blood concentration of FK506 (ng/ml) at its maximal effect on the ECG was assessed using a microparticle immunoenzymatical method (University Hospital Lapeyronie, Biochemistry laboratory).
Cell isolation and cellular electrophysiology. Rats were heparinized and anaesthetized, and ventricular cells enzymatically isolated as described before (10 channels was measured as the integrated surface area during the depolarization. All averaged data are presented as mean ±SEM. Statistics were performed using Student's t test (for paired or unpaired samples). Differences were considered significant with *p<0.05, highly significant with **p<0.01 and extremely significant with ***p<0.001.
Solutions. FK506 was prepared as 25 mmol/L stock solutions in DMSO. Nifedipine (Sigma) was prepared as 10 mmol/l stock solution in ethanol. On the day of experiments, aliquots were diluted to the desired concentrations in the perfusion solution. Control and test solutions were applied as described (1) . For in vivo experiments, Prograf injectable solution was prepared daily at the desired concentration in an isotonic saline solution. FK506 and Prograf were generous gifs from Fujisawa Pharmaceutical Co., Ltd, Osaka, Japan.
Simulation. We used the model of Pandit et al. (26) in conjunction with a mechanistic representation of the frequency-dependent facilitation of I CaL , which we described before (17, 28) . Differential equations derived from the structure of the complete model were solved using a 
RESULTS

Effect of FK506 on the QT Interval.
Holter recordings were performed during 12 hours overnight, corresponding to the active period of animals. Fig. 1A shows a representative evolution of the ECG after injection of 3 mg/kg FK506 (see Methods). Prolongation of the QT/QTc interval started 40 min after injection and lasted for several hours (Fig. 1B) . Similar effects were observed in 4 different animals. Measurements of the blood concentration of FK506 during its maximal effect in other animals demonstrated the presence of circulating FK506 at concentrations varying between 40 and 220 ng/ml (i.e., range 50-250 nmol/L). We concluded therefore that FK506 could prolong the QTc interval also in rat, as described previously in human (see introduction) and in an experimental model such as the guinea pig (22, 23) . We did not detect arrhythmic events in these experiments.
Use-dependent effects of (Fig. 2Ba,b) . This effect was accompanied by a depolarization of the RMP to -78.8±0.4 mV (***p<0.001). Furthermore, high pacing rates triggered EADs (Fig. 2Ba) in 59% of cells (n = 17). EADs developed at plateau potentials. All these effects were reversible upon washout of FK506 for at least 10 min. They were also observed at 5 ?mol/L but they were less pronounced than at 25 ?mol/L. Hence, most of the study was conducted using this latter concentration (see also ref. (7, 8, 6) ).
Effect of FK506 on I
CaL . An increase in the APD is expected to reflect an increase in an inward current or/and a decrease in an outward current. We previously related frequencydependent changes of rat ventricular AP duration to changes in I CaL (10) . We reasoned that I CaL could be involved in the pacing-dependent effects and in the EADs induced by FK506. This hypothesis was further supported by the fact that the Ca 3C ) and in I CaL decay kinetics (Fig. 3Da) and with no use dependence. The decrease was unrelated to spontaneous run down of I CaL peak amplitude since recovery was observed after wash-out of the drug (Fig. 3E) . Detailed analysis showed that the amplitude of Af (see methods), the Ca 2+ -dependent fast inactivating component (1), was decreased with no change in the slow component As (Fig. 3Cb ) which resulted into a decrease of the [Af/(Af+As)] ratio. This decrease of Af, therefore, accounted for the decrease in global peak I CaL (Fig. 3Db) . Importantly, the frequency-dependent facilitation of I CaL , which we routinely assessed by changing the rate from 0.1 Hz to 3.3 Hz (10), persisted consistently (Fig. 3E) . In the examples shown in Fig. 3E , Ca 2+ entry, measured as integrated surface area during depolarizations, was increased by 55% after the change from 0.1 Hz to 3.3 Hz in control conditions (top panel). In the presence of FK506 (middle panel), the increase was still important (40%) and exceeded largely the reduction induced by FK506 (-6% of Ca 2+ entry during the depolarization) that occurred mainly on current peak amplitude. Therefore, we concluded that the slowing of I CaL decay kinetics can clearly be a major factor in the triggering of EADs.
Effect of FK506 on I to and I K . FK506 decreased both I to and I K (Fig. 4Aa) . Steady-state inhibition of I K was obtained within less than 2 min whereas steady-state inhibition of I to needed more than 10 min (Fig. 4Ab) . FK506 blocked I K nearly completely at all voltages whereas I to was much less sensitive (Fig. 4Bab) . Inhibition of I to was slightly enhanced by higher pacing rates (less than 10% of the remaining peak current, data not shown) as reported before (7). (Fig. 6Aa ) that were associated with increased diastolic (Fig. 6Ab ) and systolic Ca 2+ (Fig. 6Ac) exchanger activity and, thereby, induce inward I NaCa , we replaced Na + by equimolar Li + to block I Na-Ca . EADs were abolished in this condition, though rapid pacing-induced prolongation of the AP was still observed (Fig. 6B) .
AP Simulation.
We assessed the mechanistic details of the pacing-dependent effect of FK506 on the AP using a theoretical model of rat ventricular cells (see Methods). To mimic the effect of FK506, we decreased all conductances inhibited by FK506 consistently with experimental observations: 25% for I CaL , 20% for I to , 80% for I K and 40% for I K1 . We also shifted the reversal Use-dependent effects of FK506 11 potential of I K1 (-3 mV). At a pacing rate of 0.1 Hz, simulations resulted in RMP hyperpolarization and prolongation of the repolarizing phase of the AP (Fig. 7Aa) . These effects were quite consistent with the experimental effects of FK506 (Fig. 2Aa) . The shift of I K1 was required to produce the hyperpolarization, but not sufficient per se to induce the AP prolongation (data not shown). Simulation with only a decrease in I K1 showed that block of this current by FK506 accounts for most of the effect of the drug on the AP at low pacing rates (data not shown). An increase in the pacing rate from 0.1 Hz to 3.3 Hz immediately promoted a depolarization of the RMP, a marked prolongation of the AP and occurrence of EADs, reproducing all the effects of FK506 (Fig. 7Ba,b) . These effects were antagonized by suppressing facilitation of I CaL (i.e., by suppressing frequency-dependent slowing of the decay of I CaL in the model) (Fig. 7C) , which indicated that this current has a central role. However, the extent of block of I to is also be potentially critical (Fig. 7D) . Finally, when I NaCa was set to 0, EADS were prevented though a substantial prolongation of the AP remained (Fig. 7E ) as observed experimentally (Fig. 6B) .
DISCUSSION
FK506 is a promising immunosuppressant agent (27). FK506 acts primarily as an inhibitor of
T-cell response by preventing dephosphorylation and translocation of the nuclear factor of activated T cells (NFAT). FK506 binds to its cellular target, the FKBPs among which FKBP12.6 is tightly associated to the RyR 2 , and plays a role in the regulation of Ca FK506 has no effect on I CaL peak amplitude (6, 20, 34) . A possible explanation for this discrepancy with our results is that, in these studies, I CaL was evoked from depolarized HP (-40 mV). Depolarizing the HP to this level indeed decreases A f preferentially (1, 28) , which might prevent further effect of FK506 on I CaL . Importantly, despite partial inhibition of peak I CaL by FK506, high pacing induced facilitation of I CaL persisted. Facilitation compensated largely the decreasing effect of FK506 on current peak amplitude and provided the triggering event for
EADs here. Large increases in Ca 2+ entry were indeed still promoted by high rates in presence of FK506. Both nifedipine effect (Fig. 3A) and numerical simulation (Fig. 7C) K1 . I K1 has a major role in maintaining the RMP near the high negative K + equilibrium potential in ventricular cells (24) . Moreover, between the RMP and -30 mV as during the AP plateau, the outward current will contribute to phase III repolarization (21) . In contrast to its effects on I to and I K , the inhibition of I K1 by FK506 was diminished in the presence of intracellular Ca 2+ buffers (unpublished results), which may be interpreted as reflecting Ca 2+ -dependent block of the outward flow due to increased rectification of I K1 channels (19, 39) . The consequences of this block were primarily a prolongation of the AP late phase, and a hyperpolarization of the RMP due to a leftward shift in the I K1 I-V curve. Block of the outward current is indeed expected to shift the K + Nernst potential (E K ) from its resting value to more hyperpolarized potentials (4) . From a physiological point of view, inhibition of I K1 might be, at least partially, involved in the prolongation of the QTc interval observed experimentally (Fig. 1) .
Selective block of I K1 by Ba 2+ has been associated with prolonged QTc in isolated rabbit hearts (37) . Similarly, in guinea-pig hearts probed with Kir2.1 overexpression and dominant-negative suppression, the QTc interval is prolonged by I K1 suppression (21) .
FK506-induced AP prolongation at low pacing rate. FK506 inhibits various currents
involved in the repolarizing phase of the AP. These currents have two opposite roles: depolarization (I CaL ) and repolarization (I to , I K1 , I K ). In theory, inhibition of I CaL shortens the AP plateau whereas inhibition of I to , I K1 and/or I K would delay repolarization. At low pacing rate (0.1 Hz), FK506 has stronger effect on the late phase of the AP. In addition, it hyperpolarizes the RMP. The opposite effects on I to and I CaL are probably more or less counterbalancing each other during the early phase. Since I K has very little contribution in rat ventricular cells (4, 12), we Use-dependent effects of FK506 14 suggest therefore that most of the prolongation of the AP at low pacing rate reflects inhibition of I K1 . This hypothesis was confirmed by computer simulation, which reproduced the I K1 -mediated effect of FK506 on both AP duration and RMP.
High pacing rates and EADs: mechanisms. AP duration is an important arrhythmogenic determinant. AP lengthening can result in the occurrence of EADs (36) . In normal conditions, high pacing rates enhance AP duration in rat ventricular cells. This is a highly dynamic process that involves facilitation of I CaL and occurs through beat-to-beat adaptation (10, 35) . We show here that rapid pacing-induced increase in AP duration is enhanced by FK506. Both the plateau phase and late repolarization are markedly prolonged, and EADs eventually develop at plateau potentials. Despite partial inhibition of I CaL by FK506, high pacing induced facilitation of I CaL persists and plays a key role (Fig. 7C) . Although facilitation of I CaL is not enhanced per se, persistence of the slowing of I CaL decay kinetics after pacing acceleration, provides sufficient net depolarizing current during the AP plateau (Fig. 7C) transients, as reported by others in rat and mouse ventricular myocytes, (6, 20, 34) . Arrhythmia is associated with these increases (Fig. 6A) . FK506 has probably no direct effect on the Na + -Ca 2+ Use-dependent effects of FK506 15 exchanger (20, 34) . However, our data suggest that forward I NaCa is important (Fig. 6B) setting I NaCa to zero prevents EADs (Fig. 7E) . Therefore, we conclude that enhancement of I NaCa also contributes to acceleration-induced EADs (2) in the presence of FK506. However, the fact that changes in Ca The effect on I K1 , responsible for prolonged terminal repolarization of the AP, is the main effect at low pacing rates, and it has probably a significant role in the QT prolongation. We demonstrated that use-dependent increase in Ca 
